

Pneumococcal Vaccine Market Competition Analysis 2025: How Players Are Shaping Growth

*The Business Research Company's
Pneumococcal Vaccine Market
Competition Analysis 2025: How Players
Are Shaping Growth*

LONDON, GREATER LONDON, UNITED
KINGDOM, January 2, 2026
/EINPresswire.com/ -- "The

Pneumococcal Vaccine market is dominated by a mix of global vaccine manufacturers and regional public-health partners. Companies are focusing on expanded-valency conjugate vaccines, broader immunization coverage, and strong regulatory alignment to strengthen market presence and support global disease-prevention goals. Increasing collaboration with public health agencies, global vaccine alliances, and national immunization programs is driving wider access and sustained demand. Understanding the competitive

“

Expected to grow to \$11.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%”


*The Business Research
Company*

landscape is essential for stakeholders seeking opportunities in next-generation vaccine development, large-scale procurement contracts, and long-term strategic partnerships.

Which Market Player Is Leading the Pneumococcal Vaccine Market?

According to our research, Pfizer Inc. led global sales in

2023 with a 3% market share. The Biopharmaceuticals Group (Biopharma) division of the company partially involved in the pneumococcal vaccine market, provides the commercializes medicines and vaccines for various therapeutic areas such as oncology, inflammation and immunology, and rare diseases. Its product portfolio includes Ibrance, Eliquis – Xeljanz, Chantix and Champix, Student, Retacrit, Lorbrena and Braftovi, Xtandi, Vindel/Vyndamax, Pristiq, Inlyta, Comirnaty/BNT162b2, IVIg Products, FSME/IMMUN-TicoVac, Trumenba, Sulperazon, Medrol,



Zavicefta, Zithromax, Vfend, Panzyga, Paxlovid, Prevenar 13/Prevnar 13, Enbrel, and others.

How Concentrated Is the Pneumococcal Vaccine Market?

The market is concentrated, with the top 6 players accounting for 100% of total market revenue in 2023. This level of concentration reflects the industry's high entry barriers—driven by complex vaccine-development requirements, stringent regulatory pathways, substantial clinical-trial investments, and the critical need for proven immunogenicity and safety. Leading players such as Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., and Biological E. Limited dominate through established production capabilities, broad serotype coverage, and strong integration with national immunization programs and global health agencies. As global efforts intensify to expand protection against pneumococcal disease—particularly with higher-valency and next-generation conjugate vaccines—strategic partnerships, public-health collaborations, and sustained R&D investment are expected to reinforce the leadership positions of these major manufacturers.

- Leading companies include:
 - o Pfizer Inc. (81%)
 - o Merck & Co. Inc. (5%)
 - o GlaxoSmithKline plc (5%)
 - o Serum Institute of India Pvt. Ltd. (4%)
 - o Walvax Biotechnology Co. Ltd. (3%)
 - o Biological E. Limited (2%)

Request a free sample of [Pneumococcal Vaccine Market report](https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp)
https://www.thebusinessresearchcompany.com/sample_request?id=11950&type=smp

Which Companies Are Leading Across Different Regions?

- North America: Biological E. Limited, Sinovac Biotech Ltd., Panacea Biotec Limited, Merck & Co., Inc., Pfizer Inc., GPN Vaccines Pty Ltd, Vaxcyte, Inc., GlaxoSmithKline plc, Sanofi Pasteur Inc., Panacea Biotec Ltd., Pfizer Canada ULC, and GSK Canada. are leading companies in this region.
- Asia Pacific: SK Bioscience Co., Ltd., Pfizer, Merck Sharp & Dohme, Sanofi India, GSK India, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., Serum Institute of India Private Limited, Yuxi Walvax Biotechnology Co., Ltd., Biological E. Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, Panacea Biotec, Tergene Biotech, CanSinoBIO, Abbott India Ltd., are leading companies in this region.
- Western Europe: Merck Sharp & Dohme, GlaxoSmithKline (GSK), Sanofi S.A., PnuVax Incorporated, and Pfizer are leading companies in this region.
- Eastern Europe: GlaxoSmithKline plc, Biological E. Limited, Sinovac Biotech Ltd., Panacea Biotec Limited, Pfizer Inc., Nanolek LLC, and NPO Petrovax Pharm LLC. are leading companies in this region.
- South America: Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Biological E. Limited, SK

bioscience Co., Ltd., and Sinergium Biotech S.A. are leading companies in this region.

What Are the Major Competitive Trends in the Market?

- Innovative pneumococcal vaccine enhances paediatric immunization by targeting local disease burden is transforming improving vaccine effectiveness, address local public health needs and reduce dependence on imported products.
- Example: CanSino Biologics Inc iPneucia (June 2025) assigns unique clinical data show strong antibody responses against key serotypes prevalent in Chinese children.
- These innovative dual carriers Cross-Reacting Material 197 (CRM197 + tetanus toxoid), it enhances immunogenicity while minimizing interference with other vaccines.

Which Strategies Are Companies Adopting to Stay Ahead?

- Launching new vaccine products to strengthen market position
- Enhancing R&D investments to accelerate next-generation pneumococcal vaccine development
- Focusing on serotype expansion and immunogenicity optimization to address evolving disease patterns
- Leveraging advanced conjugation technologies for improved vaccine efficacy and stability.

Access the detailed Pneumococcal Vaccine Market report here

<https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report>

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/879429857>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.